您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2015, Vol. 53 ›› Issue (7): 53-57.doi: 10.6040/j.issn.1671-7554.0.2014.841

• 临床医学 • 上一篇    下一篇

BSD2000相控阵聚焦深部热疗联合TP方案化疗治疗晚期卵巢癌的临床效果

崔勇1, 张荣香2, 王福立3, 王国颖4, 冯建林5, 张海霞1   

  1. 1. 寿光市人民医院肿瘤科, 山东 寿光 262700;
    2. 寿光市人民医院门诊部, 山东 寿光 262700;
    3. 淄博市中心医院肿瘤科, 山东 淄博 255000;
    4. 潍坊医学院附属医院内科, 山东 潍坊 261000;
    5. 寿光市人民医院影像科, 山东 寿光 262700
  • 收稿日期:2014-11-16 修回日期:2015-03-02 发布日期:2015-07-10
  • 通讯作者: 王福立。E-mail:wfl19820607@163.com E-mail:wfl19820607@163.com
  • 基金资助:
    潍坊市科学技术发展计划(20122033)

Clinical efficacy of BSD2000 deep hyperthermia combined with chemotherapy of TP regimen for advanced ovarian cancer

CUI Yong1, ZHANG Rongxiang2, WANG Fuli3, WANG Guoying4, FENG Jianlin5, ZHANG Haixia1   

  1. 1. Department of Oncology, Shouguang People's Hospital, Shouguang 262700, Shandong, China;
    2. Department of Out-Patient, Shouguang People's Hospital, Shouguang 262700, Shandong, China;
    3. Department of Oncology, Zibo Central Hospital, Zibo 255000, Shandong, China;
    4. Department of Internal Medicine, Affiliated Hospital of Weifang Medical University, Weifang 261000, Shandong, China;
    5. Department of Radiology, Shouguang People's Hospital, Shouguang 262700, Shandong, China
  • Received:2014-11-16 Revised:2015-03-02 Published:2015-07-10

PDF (PC)

634

摘要： 目的 观察BSD2000相控阵聚焦深部热疗联合多西他赛+顺铂(TP)方案化疗治疗晚期卵巢癌的临床效果。方法 将39例晚期卵巢癌患者随机分为两组, 治疗组20例, 给予BSD2000相控阵聚焦深部热疗+TP方案化疗;对照组19例, 给予TP方案化疗。结果 治疗组病灶的客观有效率(RR)高于对照组(90.0% vs 62.2%, P<0.05)。治疗组腹水的RR高于对照组(55.0% vs 21.1%, P<0.05)。治疗组生活质量评分改善率为70.0%, 对照组改善率为31.6%,两组比较差异有统计学意义(P<0.05)。治疗组与对照组的1年生存率分别为77.8%和66.7%, 2年生存率分别为55.5%和44.4%, 两组1年和2年生存率比较差异无统计学意义(P均>0.05)。两组患者不良反应发生率的差异无统计学意义(P>0.05)。结论 BSD2000相控阵聚焦深部热疗联合TP方案化疗可以提高晚期卵巢癌的客观有效率、改善生活质量, 不良反应可耐受。

关键词: 卵巢肿瘤, 热疗, 顺铂, 药物疗法, 多西他赛

Abstract: Objective To observe the clinical efficacy of BSD2000 deep hyperthermia combined with chemotherapy of docetaxel plus cisplatin (TP) regimen in the treatment of advanced ovarian cancer. Methods A total of 39 patients with advanced ovarian cancer were randomly divided into two groups: treatment group (n=20) receiving BSD2000 deep hyperthermia plus chemotherapy of TP regimen, and control group (n=19) undergoing chemotherapy of TP regimen. Results For the treatment and control group, the objective response rate (RR) was 90.0% vs 62.2%, RR of ascites was 55.0% vs 21.1%, quality of life score was 70.0% vs 31.6%, with statistically significant differences between the two groups (all P<0.05). The one-year and two-year survival rates for the treatment and control group were 77.8% vs 66.7% and 55.5% vs 44.4%, with no statistical difference (both P>0.05). Conclusion BSD2000 deephyperthermia combined with chemotherapy of TP regimen can significantly improve objective response rate and quality of life for patients with advanced ovarian cancer, and toxicity can be well tolerated.

Key words: Hyperthermia, Ovarian cancer, Docetaxel, Cisplatin, Drug therapy

中图分类号: 

  • R737.31
[1] Burger RA, Brady MF, Bookman MA, et al. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a gynecologic oncology group study[J]. J Clin Oncol, 2014, 32(12):1210-1217.
[2] Suidan RS, St Clair CM, Lee SJ, et al. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer[J]. Gynecol Oncol, 2014, 134(3):468-472.
[3] Toffart AC, Moro-Sibilot D, Couraud S, et al. Evaluation of RECIST in chemotherapy-treated lung cancer: the pharmacogenoscan study[J]. BMC Cancer, 2014, 14(1):989.
[4] Müller V, Fuxius S, Steffens CC, et al. Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study[J]. Oncol Res Treat, 2014, 37(12):748-755.
[5] Kautio AL, Haanp M, Kautiainen H, et al. Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy[J]. Anticancer Res, 2011, 31(10):3493-3496.
[6] Teefey P, Bou Zgheib N, Apte SM, et al. Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers[J]. Am J Obstet Gynecol, 2013, 208(6):501-507.
[7] Muenyi CS, Trivedi AP, Helm CW, et al. Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells[J]. Toxicol Sci, 2014, 139(1):74-82.
[8] 杨孟祥, 赵军, 王彦文. BSD2000深部热疗联合PT方案化疗在非小细胞肺癌中的应用[J]. 中国肺癌杂志, 2010, 13(2):132-135. YANG Mengxiang, ZHAO Jun, WANG Yanwen. BSD2000 deep hyperthermia combined with chemotherapy of PT regimen in patients with non-small cell lung cancer[J]. Chinese Journal of Lung Cancer, 2010, 13(2):132-135.
[9] Yan SY, Chen MM, Fan JG, et al. Therapeutic mechanism of treating SMMC-7721 liver cancer cells with magnetic fluid hyperthermia using Fe2O3 nanoparticles[J]. Braz J Med Biol Res, 2014, 47(11):947-959.
[10] Wessalowski R, Schneider DT, Mils O, et al. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours:an open-label, non-randomised, single-institution, phase 2 study[J]. Lancet Oncol, 2013, 14(9):843-852.
[11] Bruggmoser G, Bauchowitz S, Canters R, et al. Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia:quality management in regional deep hyperthermia[J]. Strahlenther Onkol, 2012, 188(Suppl 2):198-211.
[12] Bruggmoser G, Bauchowitz S, Canters R, et al. Quality assurance for clinical studies in regional deep hyperthermia[J]. Strahlenther Onkol, 2011, 187(10):605-610.
[13] 张力, 李毅学, 张立广, 等. 热疗诱导人肝癌细胞HepG2的凋亡[J]. 中国老年学杂志, 2013, 33(6):1342-1344.
[14] 李灿宇, 张自森, 薛长年, 等. 热灌注顺铂治疗晚期卵巢癌恶性腹腔积液的临床疗效[J]. 中国老年学杂志, 2012, 32(17):3656-3658.
[15] 赵军, 王宝中, 盛延兴, 等. 放化疗结合相控阵聚焦热疗治疗直肠癌术后局部区域复发的临床观察[J]. 中华肿瘤防治杂志, 2009, 16(21):1691-1693. ZHAO Jun, WANG Baozhong, SHENG Yanxing, et al. Curative effect of radiotherapy and chemotherapy combined with focus phased array thermotherapy for rectal cancer with recurrence after resection[J]. Chinese Journal of Cancer Prevention and Treatment, 2009, 16(21):1691-1693.
[1] 王伟 王沂峰 张岭梅 林琼燕 黄菊. 人卵巢癌OVCAR3细胞系中侧群细胞的分离及其成瘤性、侵袭性的实验研究[J]. 山东大学学报(医学版), 2209, 47(6): 8-11.
[2] 王亚楠,梁传杰,贾梦琪,苑辉卿. 二硫键异构酶TMX1促进肺癌化疗耐药[J]. 山东大学学报 (医学版), 2023, 61(8): 31-39.
[3] 徐兵,李勇,刘明,刘永辉. 沉默PRRX1基因表达可增强前列腺癌耐药细胞株PC-3/DTX对多西他赛的敏感性[J]. 山东大学学报 (医学版), 2021, 59(6): 103-110.
[4] 索东阳,申飞,郭皓,刘力畅,杨惠敏,杨向东. Tim-3在药物性急性肾损伤动物模型中的表达及作用机制[J]. 山东大学学报 (医学版), 2020, 1(7): 1-6.
[5] 胡蓉,王蓓. 卵巢环状小管性索瘤超声表现1例并文献复习[J]. 山东大学学报 (医学版), 2019, 57(6): 122-124.
[6] 王聪,朱玲,万云焱,姚周虹,李德志,许小婷,徐鹏飞,林殿杰. 重组人血管内皮抑制素不同给药途径联合顺铂对小鼠Lewis肺癌的疗效[J]. 山东大学学报 (医学版), 2019, 57(5): 93-98.
[7] 张志慧,刘延国,肖丰启,马道新,王秀问. 顺铂对肿瘤间充质干细胞中IL-6表达的调控及p38MAPK通路参与机制[J]. 山东大学学报 (医学版), 2019, 57(3): 1-6.
[8] 薛婷,王黎明,焦今文,李勇,郭爱莲,赵涵. siRNA介导RRM2基因沉默治疗人卵巢癌裸鼠移植瘤[J]. 山东大学学报 (医学版), 2019, 57(10): 74-79.
[9] 律慧敏,张梦玮,牛李敏,曾惠爱,闫敏. 国产多西他赛单药治疗晚期乳腺癌的疗效及安全性[J]. 山东大学学报 (医学版), 2018, 56(1): 45-49.
[10] 丁长宽,陈健行. 蛋白酶体抑制剂硼替佐米联合顺铂对宫颈癌细胞增殖的影响[J]. 山东大学学报 (医学版), 2018, 56(1): 70-75.
[11] 赵明,牛杰,李芳芹,王爱红,庞秋霞,陈美霓,周丽珍,赵菊梅. 盐霉素联合顺铂对人胃癌细胞MKN-45增殖和凋亡的影响[J]. 山东大学学报（医学版）, 2017, 55(5): 31-35.
[12] 刘朝娣,邓凯,靳先文,宋歌声,张成琪. 能谱CT对卵巢原发良恶性肿瘤的鉴别[J]. 山东大学学报 (医学版), 2017, 55(12): 43-50.
[13] 赵路,矫俊,张腾,焦薪霖,崔保霞. 肝X受体在卵巢癌组织中的表达及T0901317在卵巢癌细胞系SKOV3中的作用[J]. 山东大学学报（医学版）, 2017, 55(1): 49-53.
[14] 肖俊超,蒋雯,南慧,王培荣. 重组腺病毒35型纤毛突蛋白增强西妥昔单抗的抗卵巢癌作用[J]. 山东大学学报（医学版）, 2016, 54(5): 1-5.
[15] 张春霞,邹存华,宋冬冬,余江. P38MAPK信号通路对卵巢癌中尿激酶型纤维蛋白酶原激活剂的影响[J]. 山东大学学报（医学版）, 2016, 54(2): 68-74.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发